Boron neutron capture therapy for newly diagnosed glioblastoma

Shinji Kawabata, Shin Ichi Miyatake, Toshihiko Kuroiwa, Kunio Yokoyama, Atsushi Doi, Kyoko Iida, Shiro Miyata, Naosuke Nonoguchi, Hiroyuki Michiue, Masatsugu Takahashi, Taisuke Inomata, Yoshio Imahori, Mitsunori Kirihata, Yoshinori Sakurai, Akira Maruhashi, Hiroaki Kumada, Koji Ono

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma (NDGB) patients, especially in combination with X-ray treatment (XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 were treated with only BNCT (protocol 1), and the last 11 were treated with BNCT followed by XRT of 20 to 30 Gy (protocol 2) to reduce the possibility of local tumor recurrence. No chemotherapy was applied until tumor progression was observed. The patients treated with BNCT (protocol 1 plus 2) showed a significant survival prolongation compared with the institutional historical controls. BNCT also showed favorable results in correspondence with the RTOG- and EORTC-RPA subclasses. The median survival time (MST) was 15.6 months for protocols 1 and 2 together. For protocol 2, the MST was 23.5 months. The main causes of death were cerebrospinal fluid dissemination as well as local recurrence. Our modified BNCT protocol showed favorable results of patients with NDGB not only for those with good prognoses but also for those with poor prognoses.

Original languageEnglish
Pages (from-to)51-60
Number of pages10
JournalJournal of radiation research
Volume50
Issue number1
DOIs
Publication statusPublished - Mar 24 2009

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Boron neutron capture therapy for newly diagnosed glioblastoma'. Together they form a unique fingerprint.

Cite this